The Shared Genetic Basis of Hyperuricemia, Gout, and Kidney Function.


Journal

Seminars in nephrology
ISSN: 1558-4488
Titre abrégé: Semin Nephrol
Pays: United States
ID NLM: 8110298

Informations de publication

Date de publication:
11 2020
Historique:
entrez: 8 3 2021
pubmed: 9 3 2021
medline: 15 12 2021
Statut: ppublish

Résumé

Increased urate levels and gout correlate with chronic kidney disease with consensus that the primary driver of this relationship is reduced kidney function. However, a comparison of results of genome-wide association studies in serum urate levels and kidney function indicate a more complex situation. Approximately 20% of loci are shared-comprised of those in which the urate-raising allele associates with reduced kidney function, the vice versa situation, and those in which the signals/alleles are different. Although there is very little known regarding the molecular basis of the shared genetic relationship, it is clear that there is no major role for urate transporters and associated transportasome machinery. Some loci, however, do provide clues. The ATXN2 locus, with a shared signal, is one of only a small number of master regulators of expression by chromatin interaction, regulating expression of genes relevant for cholesterol and blood pressure. This suggests a role for systemic metabolic alteration. At HNF4A there is genetic heterogeneity with different genetic variants conferring risk to hyperuricemia and chronic kidney disease, suggesting different pathways. Interestingly, the shared loci congregate in the olfactory receptor pathway. The genome-wide association studies have generated a range of experimentally testable hypotheses that should provide insights into the shared pathogenesis of hyperuricemia/gout and chronic kidney disease.

Identifiants

pubmed: 33678313
pii: S0270-9295(20)30136-4
doi: 10.1016/j.semnephrol.2020.12.002
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

586-599

Subventions

Organisme : NIAMS NIH HHS
ID : P50 AR060772
Pays : United States

Informations de copyright

Published by Elsevier Inc.

Auteurs

Megan P Leask (MP)

Department of Biochemistry, University of Otago, Dunedin, New Zealand; Division of Clinical Immunology and Rheumatology, University of Alabama Birmingham, Birmingham, AL.

Nicholas A Sumpter (NA)

Division of Clinical Immunology and Rheumatology, University of Alabama Birmingham, Birmingham, AL.

Alexa S Lupi (AS)

Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI; Institute for Quantitative Health Science and Engineering, Systems Biology, Michigan State University, East Lansing, MI.

Ana I Vazquez (AI)

Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI; Institute for Quantitative Health Science and Engineering, Systems Biology, Michigan State University, East Lansing, MI.

Richard J Reynolds (RJ)

Division of Clinical Immunology and Rheumatology, University of Alabama Birmingham, Birmingham, AL.

David B Mount (DB)

Renal Division, Brigham and Women's Hospital, VA Boston Healthcare System, Harvard Medical School, Boston, MA.

Tony R Merriman (TR)

Department of Biochemistry, University of Otago, Dunedin, New Zealand; Division of Clinical Immunology and Rheumatology, University of Alabama Birmingham, Birmingham, AL. Electronic address: tony.merriman@otago.ac.nz.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH